Head/Neck Cancer

Top Story

Gottlieb sees ‘watershed opportunity’ to shape future of FDA’s regulatory process

Gottlieb sees ‘watershed opportunity’ to shape future of FDA’s regulatory process
November 16, 2017

WASHINGTON — When diagnosed with Hodgkin lymphoma at the age of 33 years, FDA Commissioner Scott Gottlieb, MD, was told he had a 90% chance of survival.

“Ninety percent doesn’t sound so good if it’s you,” Gottlieb, now 44, told HemOnc Today following a keynote presentation at the Friends of Cancer Research Annual Meeting. “So, to me, that 10% sounded pretty grim.”

FDA News

FDA authorizes IMPACT test to rapidly identify cancer mutations

November 15, 2017
The FDA today authorized Integrated Mutation Profiling of Actionable Cancer Targets, or IMPACT, an in vitro diagnostic test that uses next-generation sequencing to…

Loxo Oncology, Bayer announce partnership for targeted cancer therapies

November 14, 2017
Loxo Oncology and Bayer have entered into a global partnership to develop and commercialize two targeted cancer therapies. The partnership is for larotrectinib…
In the Journals Plus

ASCO: Even light alcohol use increases risk for cancer

November 7, 2017
Alcohol use — whether light, moderate or heavy — increases cancer risk, and public health measures are needed to reduce high-risk alcohol consumption…
More Headlines »
CME

Hot Topics in Metastatic Breast Cancer Management: Clinical Advances with CDK4/6 Inhibitors

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

While the mortality rates for advanced or metastatic breast cancer (MBC) have steadily decreased, in part due to…
More »
Video
Meeting News

VIDEO: Visiting expert program helps community providers learn about immuno-oncology

June 12, 2017
More »
Resource Centers

CME

Breakthroughs in the Treatment of Bladder Cancer

This activity is supported by an educational grant from Bristol-Myers Squibb.

Assessment of immune checkpoint blockade inhibitors in the treatment of bladder cancer have demonstrated significant…
More »